GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease

Target: GAS6/TAM receptor complex Composite Score: 0.513 Price: $0.53▲3.9% Citation Quality: Pending neuroinflammation Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.513

Top 65% of 1875 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C+ Mech. Plausibility 15% 0.51 Top 76%

C+ Evidence Strength 15% 0.55 Top 47%

A Novelty 12% 0.80 Top 25%

C Feasibility 12% 0.42 Top 82%

B Impact 12% 0.62 Top 66%

C Druggability 10% 0.40 Top 81%

D Safety Profile 8% 0.35 Top 89%

C+ Competition 6% 0.58 Top 62%

C+ Data Availability 5% 0.52 Top 68%

C+ Reproducibility 5% 0.55 Top 55%

Evidence

5 supporting | 4 opposing

Citation quality: 60%

Debates

1 session B+

Avg quality: 0.75

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

The finding that Mertk/Axl deficiency increases viral susceptibility contradicts the established paradigm that TAM receptors dampen antiviral immunity. This unexpected protective role challenges current understanding of TAM receptor function in neuroinvasive infections. Gap type: contradiction Source paper: The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity. (2015, Nature medicine, PMID:26523970)

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease starts from the claim that modulating GAS6/TAM receptor complex within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease starts from the claim that modulating GAS6/TAM receptor complex within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease starts from the claim that Blood-brain barrier breakdown allows peripheral immune cells to infiltrate the CNS, exacerbating neuroinflammation and synaptic damage in AD. GAS6-activated TAM receptors (particularly AXL and MERTK) maintain BBB integrity by promoting tight junction protein expression and suppressing matrix metalloproteinase activity, preventing harmful leukocyte extravasation. Framed more explicitly, the hypothesis centers GAS6/TAM receptor complex within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating GAS6/TAM receptor complex or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.55, novelty 0.80, feasibility 0.42, impact 0.62, mechanistic plausibility 0.51, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `GAS6/TAM receptor complex` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of GAS6/TAM receptor complex or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. MERTK deficiency increases viral neuroinvasion due to BBB breakdown. Identifier 26523970. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. GAS6 identified as potential therapeutic target for viral encephalitis neuroinflammation. Identifier 39300526. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Blood coagulation pathway highly enriched in TAM receptor interactome (GO:0007596, p=5.69e-11). Identifier computational:string_enrichment. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Plasma sAXL correlates with locus coeruleus integrity in AD patients. Identifier 40596706. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. GAS6 overexpression in APP/PS1 mice induces inflammation despite reducing plaques - directly contradicts neuroprotective mechanism. Identifier 35130912. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. BBB dysfunction in chronic AD involves pericyte degeneration, basement membrane damage that TAM receptors cannot reverse. Identifier skeptic:feasibility. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. TAM receptors in cancer promote angiogenesis and metastasis - same vascular effects could be harmful in brain. Identifier 27834845. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Coagulation pathway enrichment reflects vascular homeostasis, not necessarily BBB protection in neurodegeneration. Identifier skeptic:hypothesis4. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5119`, debate count `1`, citations `9`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates GAS6/TAM receptor complex in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting GAS6/TAM receptor complex within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers GAS6/TAM receptor complex within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating GAS6/TAM receptor complex or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.55, novelty 0.80, feasibility 0.42, impact 0.62, mechanistic plausibility 0.51, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `GAS6/TAM receptor complex` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of GAS6/TAM receptor complex or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. MERTK deficiency increases viral neuroinvasion due to BBB breakdown. Identifier 26523970. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. GAS6 identified as potential therapeutic target for viral encephalitis neuroinflammation. Identifier 39300526. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Blood coagulation pathway highly enriched in TAM receptor interactome (GO:0007596, p=5.69e-11). Identifier computational:string_enrichment. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Plasma sAXL correlates with locus coeruleus integrity in AD patients. Identifier 40596706. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. GAS6 overexpression in APP/PS1 mice induces inflammation despite reducing plaques - directly contradicts neuroprotective mechanism. Identifier 35130912. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. BBB dysfunction in chronic AD involves pericyte degeneration, basement membrane damage that TAM receptors cannot reverse. Identifier skeptic:feasibility. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. TAM receptors in cancer promote angiogenesis and metastasis - same vascular effects could be harmful in brain. Identifier 27834845. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Coagulation pathway enrichment reflects vascular homeostasis, not necessarily BBB protection in neurodegeneration. Identifier skeptic:hypothesis4. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5119`, debate count `1`, citations `9`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates GAS6/TAM receptor complex in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting GAS6/TAM receptor complex within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers GAS6/TAM receptor complex within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating GAS6/TAM receptor complex or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.55, novelty 0.80, feasibility 0.42, impact 0.62, mechanistic plausibility 0.51, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `GAS6/TAM receptor complex` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of GAS6/TAM receptor complex or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

MERTK deficiency increases viral neuroinvasion due to BBB breakdown. Identifier 26523970. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

GAS6 identified as potential therapeutic target for viral encephalitis neuroinflammation. Identifier 39300526. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Blood coagulation pathway highly enriched in TAM receptor interactome (GO:0007596, p=5.69e-11). Identifier computational:string_enrichment. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Plasma sAXL correlates with locus coeruleus integrity in AD patients. Identifier 40596706. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

GAS6 overexpression in APP/PS1 mice induces inflammation despite reducing plaques - directly contradicts neuroprotective mechanism. Identifier 35130912. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

BBB dysfunction in chronic AD involves pericyte degeneration, basement membrane damage that TAM receptors cannot reverse. Identifier skeptic:feasibility. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

TAM receptors in cancer promote angiogenesis and metastasis - same vascular effects could be harmful in brain. Identifier 27834845. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Coagulation pathway enrichment reflects vascular homeostasis, not necessarily BBB protection in neurodegeneration. Identifier skeptic:hypothesis4. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5119`, debate count `1`, citations `9`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates GAS6/TAM receptor complex in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting GAS6/TAM receptor complex within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["BBB Dysfunction"] --> B["Tight Junction Disruption"]
    B --> C["Plasma Protein Extravasation"]
    C --> D["Neuroinflammation"]
    D --> E["Neuronal Damage"]
    F["GAS6 BBB Restoration"] --> G["Tight Junction Repair"]
    G --> H["Barrier Integrity Recovery"]
    H --> I["Neuroprotection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style I fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for GAS6/TAM receptor complex from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

9 citations 9 with PMID Validation: 60% 5 supporting / 4 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 6CLIN 1GENE 2EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
MERTK deficiency increases viral neuroinvasion due…	Supporting	MECH	-	-	-	-	PMID:26523970	-
GAS6 identified as potential therapeutic target fo…	Supporting	CLIN	-	-	-	-	PMID:39300526	-
Blood coagulation pathway highly enriched in TAM r…	Supporting	MECH	-	-	-	-	PMID:computational:string_enrichment	-
Plasma sAXL correlates with locus coeruleus integr…	Supporting	GENE	-	-	-	-	PMID:40596706	-
Endocytosis pathway enriched in AD risk loci (hype…	Supporting	GENE	-	-	-	-	PMID:computational:ad_genetic_risk_loci	-
GAS6 overexpression in APP/PS1 mice induces inflam…	Opposing	MECH	-	-	-	-	PMID:35130912	-
BBB dysfunction in chronic AD involves pericyte de…	Opposing	MECH	-	-	-	-	PMID:skeptic:feasibility	-
TAM receptors in cancer promote angiogenesis and m…	Opposing	MECH	-	-	-	-	PMID:27834845	-
Coagulation pathway enrichment reflects vascular h…	Opposing	MECH	-	-	-	-	PMID:skeptic:hypothesis4	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

MERTK deficiency increases viral neuroinvasion due to BBB breakdown

PMID:26523970

GAS6 identified as potential therapeutic target for viral encephalitis neuroinflammation

PMID:39300526

Blood coagulation pathway highly enriched in TAM receptor interactome (GO:0007596, p=5.69e-11)

PMID:computational:string_enrichment

Plasma sAXL correlates with locus coeruleus integrity in AD patients

PMID:40596706

Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003)

PMID:computational:ad_genetic_risk_loci

✗ Opposing Evidence 4

GAS6 overexpression in APP/PS1 mice induces inflammation despite reducing plaques - directly contradicts neuro…▼

GAS6 overexpression in APP/PS1 mice induces inflammation despite reducing plaques - directly contradicts neuroprotective mechanism

PMID:35130912

BBB dysfunction in chronic AD involves pericyte degeneration, basement membrane damage that TAM receptors cann…▼

BBB dysfunction in chronic AD involves pericyte degeneration, basement membrane damage that TAM receptors cannot reverse

PMID:skeptic:feasibility

TAM receptors in cancer promote angiogenesis and metastasis - same vascular effects could be harmful in brain

PMID:27834845

Coagulation pathway enrichment reflects vascular homeostasis, not necessarily BBB protection in neurodegenerat…▼

Coagulation pathway enrichment reflects vascular homeostasis, not necessarily BBB protection in neurodegeneration

PMID:skeptic:hypothesis4

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-15 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection

Background Synthesis

The paradox that Mertk/Axl deficiency increases neuroinvasive viral susceptibility despite TAM receptors' known immunosuppressive function suggests context-dependent, cell-type-specific, or temporally regulated protective mechanisms beyond canonical immunosuppression.

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris

Description: Microglial Mertk activation by GAS6 promotes efferocytosis and phagocytic clearance of virus-infected apoptotic

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of TAM Receptor Neuroprotective Hypotheses

Overview Assessment

The fundamental paradox you've identified—TAM receptors' known immunosuppressive function versus their protective role against neuroinvasive viruses—is mechanistically intriguing. However, several hypotheses conflate correlative findings with causal mechanisms, and some contain internal inconsistencies with established TAM biology. Below is my systematic critique.

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance

Weaknesses in Evidence

**Cell-type specificity is assumed but no

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Drug Development Feasibility Assessment: TAM Receptor Neuroprotection in Neuroinvasive Viral Infection

Executive Summary

This assessment evaluates the seven hypotheses for TAM receptor-mediated neuroprotection against neuroinvasive viruses from a practical drug development standpoint—addressing target druggability, chemical matter availability, competitive landscape, and safety considerations.

Overall Strategic Assessment

The TAM receptor neuroprotection paradox presents a genuinely novel therapeutic opportunity, but with significant caveats:

| Strategic Factor | Assessment

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

TAM Receptor Neuroprotection Synthesis Analysis

Scoring Methodology

For each hypothesis, I integrate the Theorist's mechanistic proposals, the Skeptic's empirical critiques, and the Expert's drug development feasibility assessment to generate comprehensive 10-dimensional scores (0-1 scale).

Price History

7d Trend

↗

Rising

7d Momentum

▲ 2.7%

Volatility

Medium

0.0489

Events (7d)

⚡ Price Movement Log Recent 12 events

	Event	Price	Change	Source	Time
💬	Debate Round	$0.550	▲ 16.4%	market_dynamics	2026-04-14 23:21
💬	Debate Round	$0.473	▼ 2.4%	market_dynamics	2026-04-14 23:05
📊	Score Update	$0.484	▲ 10.3%	market_dynamics	2026-04-14 23:01
📄	New Evidence	$0.439	▼ 13.8%	market_dynamics	2026-04-14 20:42
📊	Score Update	$0.509	▲ 11.3%	market_dynamics	2026-04-14 20:16
📄	New Evidence	$0.458	▼ 11.0%	market_dynamics	2026-04-14 18:43
📊	Score Update	$0.514	▼ 19.5%	market_dynamics	2026-04-14 17:35
💬	Debate Round	$0.638	▲ 36.4%	market_dynamics	2026-04-14 15:27
📄	New Evidence	$0.468	▼ 7.5%	market_dynamics	2026-04-14 14:20
📄	New Evidence	$0.506	▼ 9.6%	evidence_update	2026-04-14 10:34
📄	New Evidence	$0.560	▲ 12.0%	evidence_update	2026-04-14 10:34
✨	Listed	$0.500		post_process	2026-04-14 10:34

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (9)

The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity.

Nature medicine (2015) · PMID:26523970

No extracted figures yet

The Receptor Tyrosine Kinase AXL in Cancer Progression.

Cancers (2022) · PMID:27834845

No extracted figures yet

Gas6 induces inflammation and reduces plaque burden but worsens behavior in a sex-dependent manner in the APP/PS1 model of Alzheimer's disease.

Journal of neuroinflammation (2022) · PMID:35130912

No extracted figures yet

GAS6 as a potential target to alleviate neuroinflammation during Japanese encephalitis in mouse models.

Journal of neuroinflammation (2024) · PMID:39300526

No extracted figures yet

Locus coeruleus integrity correlates with plasma soluble Axl levels in Alzheimer's disease patients.

Alzheimer's & dementia : the journal of the Alzheimer's Association (2025) · PMID:40596706

No extracted figures yet

Paper:computational:ad_genetic_risk_loci

No extracted figures yet

Paper:computational:string_enrichment

No extracted figures yet

Paper:skeptic:feasibility

No extracted figures yet

Paper:skeptic:hypothesis4

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role? — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-14-gap-pubmed-20260410-174607-708e8d91. The finding that Mertk/Axl deficiency increases viral susceptibility contradicts the established paradigm th …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.00

7.2th percentile (776 hypotheses)

Tokens Used

20,637

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

2579.62 tokens

Lower is better (baseline: 2000)

Cost per Citation

2293.00 tokens

Lower is better (baseline: 1000)

Cost per Score Point

41439.76 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.000

10% weight of efficiency score

Adjusted Composite

0.513

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for GAS6/TAM receptor complex.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GAS6/TAM receptor complex →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (9)

GAS6 GAS6/TAM receptor complex STAT1 TAM TYRO3 h-315367de h-929f356e neuroinflammation tam_receptor_tyrosine_kinase_signaling

Related Hypotheses

IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface

Score: 0.831 | neuroinflammation

STING Antagonists as ALS Therapeutics: Drug Repurposing

Score: 0.771 | neuroinflammation

Temporal SPP1 Inhibition During Critical Windows

Score: 0.752 | neuroinflammation

PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes

Score: 0.749 | neuroinflammation

TREM2 Crosstalk and Synergistic Activation of Phagocytic Transcriptome

Score: 0.740 | neuroinflammation

Estimated Development

Estimated Cost

Timeline

2.0 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF AAV-mediated GAS6 overexpression or AXL/MERTK agonist (UNC4240 or similar) is administered via intracerebroventricular injection to 5xFAD mice at 6 months of age (early AD pathology), THEN we will observe a statistically significant reduction in peripheral CD45+ leukocyte infiltration into the hippocampus and cortex, measured by flow cytometry, within 4 weeks post-treatment.

pending conf: 0.55

Expected outcome: ≥30% reduction in CD45+CD11b- infiltrating leukocytes in CNS parenchyma, accompanied by ≥25% increase in tight junction protein expression (claudin-5, occludin) detected by Western blot or immunofluorescence.

Falsified by: No significant reduction (p>0.05) in CNS leukocyte infiltration, or reduction in tight junction protein expression, or increased MMP-9 activity indicating BBB degradation despite GAS6/TAM activation.

Method: 5xFAD transgenic mice (B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax) treated at 6 months with AAV9-GAS6 or small molecule TAM agonist, analyzed 4 weeks post-injection by flow cytometry (CD45/CD11b) and BBB integrity markers.

IF TAM receptor signaling is genetically knocked out (Axlfl/fl Mertkfl/fl crossed with Lyzm-Cre) specifically in endothelial cells of APP/PS1 mice, THEN we will observe accelerated cognitive decline and increased neuroinflammatory cell infiltration compared to littermate controls with intact TAM signaling, assessed over an 8-week behavioral testing period.

pending conf: 0.48

Expected outcome: Significantly impaired performance on Morris water maze (≥20% increase in escape latency) and novel object recognition (≥25% reduction in discrimination index), coinciding with ≥50% increase in Iba1+ microglia/macrophages and CD3+ T-cell infiltration in hippocampus detected by immunohistochemistry.

Falsified by: No difference in cognitive performance or inflammatory cell counts between endothelial-specific TAM knockout and controls (p>0.05), indicating BBB integrity is maintained independently of TAM signaling.

Method: Endothelial-specific Axl/Mertk double knockout in APP/PS1 (B6;C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax) background, 6-month treatment cohorts, cognitive testing via Morris water maze and novel object recognition, neuropathology by Iba1/CD3 immunohistochemistry.

Knowledge Subgraph (8 edges)

Mechanism Pathway for GAS6/TAM receptor complex

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_929f356e["h-929f356e"] -->|targets| GAS6_TAM_receptor_complex["GAS6/TAM receptor complex"]
    GAS6_TAM_receptor_complex_1["GAS6/TAM receptor complex"] -->|associated with| neuroinflammation["neuroinflammation"]
    GAS6_TAM_receptor_complex_2["GAS6/TAM receptor complex"] -->|co associated with| GAS6["GAS6"]
    GAS6_TAM_receptor_complex_3["GAS6/TAM receptor complex"] -->|co associated with| TAM["TAM"]
    style h_929f356e fill:#4fc3f7,stroke:#333,color:#000
    style GAS6_TAM_receptor_complex fill:#ce93d8,stroke:#333,color:#000
    style GAS6_TAM_receptor_complex_1 fill:#ce93d8,stroke:#333,color:#000
    style neuroinflammation fill:#ef5350,stroke:#333,color:#000
    style GAS6_TAM_receptor_complex_2 fill:#ce93d8,stroke:#333,color:#000
    style GAS6 fill:#ce93d8,stroke:#333,color:#000
    style GAS6_TAM_receptor_complex_3 fill:#ce93d8,stroke:#333,color:#000
    style TAM fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 GAS6 — Search for structure Click to search RCSB PDB

🔍 Searching RCSB PDB for GAS6 structures...

Querying Protein Data Bank API

Source Analysis

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

neuroinflammation | 2026-04-14 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (1)

TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppr

Score: 0.51 · TYRO3

→ View all analysis hypotheses

GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 5

✗ Opposing Evidence 4

Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection

Background Synthesis

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris

Critical Evaluation of TAM Receptor Neuroprotective Hypotheses

Overview Assessment

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance

Weaknesses in Evidence

Drug Development Feasibility Assessment: TAM Receptor Neuroprotection in Neuroinvasive Viral Infection

Executive Summary

Overall Strategic Assessment

TAM Receptor Neuroprotection Synthesis Analysis

Scoring Methodology

Price History

Clinical Trials (0)

📚 Cited Papers (9)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (1)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (9)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (8 edges)

associated with (2)

co associated with (3)

involved in (1)

targets (2)

Mechanism Pathway for GAS6/TAM receptor complex

3D Protein Structure

Source Analysis

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

Community Feedback

Same Analysis (1)